Eqis Capital Management Inc. Acquires New Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Eqis Capital Management Inc. purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,117 shares of the medical equipment provider’s stock, valued at approximately $206,000.

A number of other large investors also recently added to or reduced their stakes in LNTH. Truist Financial Corp acquired a new position in Lantheus during the first quarter worth $283,000. Mutual of America Capital Management LLC lifted its stake in Lantheus by 5.5% during the first quarter. Mutual of America Capital Management LLC now owns 9,754 shares of the medical equipment provider’s stock worth $539,000 after purchasing an additional 505 shares in the last quarter. State of New Jersey Common Pension Fund D acquired a new position in Lantheus during the first quarter worth $4,828,000. Versor Investments LP acquired a new position in Lantheus during the first quarter worth $332,000. Finally, ClariVest Asset Management LLC acquired a new position in Lantheus during the first quarter worth $1,128,000. 98.14% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Performance

NASDAQ:LNTH opened at $59.05 on Wednesday. The firm has a market capitalization of $4.06 billion, a PE ratio of 39.63 and a beta of 0.79. The business’s fifty day moving average price is $71.19 and its 200 day moving average price is $70.54. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.13 and a quick ratio of 1.98. Lantheus Holdings, Inc. has a 12 month low of $23.51 and a 12 month high of $87.47.

Lantheus (NASDAQ:LNTHGet Rating) last posted its earnings results on Thursday, November 3rd. The medical equipment provider reported $0.90 EPS for the quarter, beating the consensus estimate of $0.75 by $0.15. The firm had revenue of $239.29 million for the quarter, compared to analyst estimates of $228.52 million. Lantheus had a return on equity of 37.77% and a net margin of 13.35%. On average, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 3.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Lantheus news, CAO Andrea Sabens sold 386 shares of the firm’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $85.83, for a total transaction of $33,130.38. Following the transaction, the chief accounting officer now owns 62,390 shares of the company’s stock, valued at $5,354,933.70. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Lantheus news, Director Brian A. Markison sold 41,812 shares of the firm’s stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $84.24, for a total transaction of $3,522,242.88. Following the transaction, the director now owns 32,608 shares of the company’s stock, valued at $2,746,897.92. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Andrea Sabens sold 386 shares of the firm’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $85.83, for a total value of $33,130.38. Following the transaction, the chief accounting officer now directly owns 62,390 shares in the company, valued at approximately $5,354,933.70. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 67,598 shares of company stock valued at $5,179,764. 1.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. B. Riley reiterated a “buy” rating on shares of Lantheus in a research note on Thursday, August 25th. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Friday, November 4th. SVB Leerink increased their price objective on Lantheus from $110.00 to $120.00 and gave the company an “outperform” rating in a research note on Tuesday. Jonestrading assumed coverage on Lantheus in a research note on Thursday, October 6th. They issued a “buy” rating and a $104.00 price objective on the stock. Finally, Mizuho assumed coverage on Lantheus in a research note on Wednesday, October 12th. They issued a “buy” rating and a $105.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $102.80.

Lantheus Company Profile

(Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Further Reading

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.